Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Kathryn A. Whitehead · GORDON RESEARCH CONFERENCES · 2024 · $25,000 — Project Summary The delivery of small molecules, proteins and biological drugs, nucleic acids, and other molecular therapies relies on the site of the disease-causing target within the body and is highly dependent on the ability to manage solubility, stability, biodistribution, and pharmacokinetics …
GREGORY W FARIS · NUMENTUS TECHNOLOGIES INC. · 2024 · $298,999 — PROJECT SUMMARY There is growing recognition that extracellular vesicles (EVs)¾micrometer- or nanometer-sized lipid particles containing protein and nucleic acid cargoes (information)¾are highly promising for new diagnostics/prognostics and experimental therapies. There is, however, a key unmet nee…
Jill A Helms · STANFORD UNIVERSITY · 2024 · $91,843 — Project abstract Maintaining the junctional epithelium (JE) is of primary importance if preservation of the cementum, periodontal ligament (PDL), and alveolar bone is to be achieved. New insights into JE barrier functions came with our discovery of a Wnt- responsive stem cell niche in the JE. In thi…
Bowen Li · UNIVERSITY OF TORONTO · 2024 · $270,000 — PROJECT SUMMARY Cystic fibrosis (CF) is a debilitating genetic disorder that predominantly impacts the lungs and pancreas due to mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Specifically, nonsense mutations, which produce truncated, non-functional proteins, accou…
Connie Wu · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2024 · $186,865 — PROJECT SUMMARY: The generation of a robust disease-specific immune response is a critical challenge in cancer immunotherapies, many of which provide clinical benefit in only a fraction of patients despite remarkable successes, and in infectious disease vaccines. Harnessing the innate immune system,…
Steven M Wolinsky · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2019 · $1,680,980 — PROJECT SUMMARY The innate immune recognition of dengue virus infection triggers antiviral immune responses; however, there is little information about how the virus regulates these measures or how these responses affect dengue virus (DENV) disease pathogenesis and immunity. System biology approa…
CHRISTOPHER P. HILL · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · 2019 · $245,589 — ABSTRACT The success of antiretroviral therapy (ART) has transformed the HIV/AIDS pandemic into a life-long chronic disease, yet major challenges remain as a growing population of ~35 million patients living with HIV continues to face significant health challenges. These include side-effects and tox…
Christopher Parks · INTERNATIONAL AIDS VACCINE INITIATIVE · 2019 · $378,183 — PROJECT SUMMARY The overall goal of this project is to develop and compare three new HIV envelope (Env) trimer delivery vaccines that are designed to mimic the natural presentation of the transmembrane glycoprotein complex (the spike) that occurs during HIV infection. Our vaccine design approach …
Barton F. Haynes · DUKE UNIVERSITY · 2019 · $1,031,297 — Vaccine trials in non-human primates challenged with R5, tier 2 SHIVs have shown protection in the presence of high levels of non-neutralizing antibodies (NNAbs), and one of the 5 Phase IIb HIV-1 vaccine efficacy trials using alum (ALVAC/AIDSVAX in RV144) showed an estimated vaccine efficacy of 31%,…
STANLEY FIELDS · UNIVERSITY OF WASHINGTON · 2019 · $295,771 — Project Summary In TR&D 1, we develop approaches to make complex changes to cells, and we generate biosensors to report on the effects of some of these changes. In the first aim, we establish strategies to rapidly and combinatorially up- or down-regulate a set of genes in a common pathway in order t…
JOHN H. SAMPSON · DUKE UNIVERSITY · 2019 · $668,450 — PROJECT SUMMARY – Project 1 We recently reported in Nature that patients with glioblastoma (GBM) randomized to receive a vaccine against Cytomegalovirus (CMV) major integument protein pp65 using a tetanus/diphtheria (Td) vaccine site preconditioning regimen had a statistically significant increase i…
Abel J Baerga-Ortiz · UNIVERSITY OF PUERTO RICO · 2019 · $1,411,724 — DESCRIPTION (provided by applicant): The development of prophylactic vaccines against HIV is of paramount importance in the global drive to halt the spread of the virus. Most new vaccine candidates are based on (or contain) versions of the envelope glycoprotein (Env), the target of the desired …
Stephen A DiGiuseppe · NORTHWESTERN UNIVERSITY AT CHICAGO · 2019 · $53,150 — ABSTRACT Poxviruses are a family of DNA viruses that have afflicted humans throughout history. Notably, smallpox devastated the human population by killing more people than any other disease. Despite being eradicated, the threat of emerging poxviruses is still a reality. New human poxviruses are st…
Richard B Kennedy · MAYO CLINIC ROCHESTER · 2019 · $775,707 — ABSTRACT The broad long-term goal of this application is to identify innate and T helper (Th) cell transcriptomic signatures of immune response and further our understanding of sex-dependent human immune responses to two unique influenza A/H3N2 vaccines in a population of older adult males and femal…
Thale Cross Jarvis · KEYSTONE SYMPOSIA · 2019 · $6,000 — ABSTRACT Support is requested for a Keystone Symposia conference entitled Molecular Approaches to Vaccines and Immune Monitoring, organized by Drs. Peter D. Kwong, Brandon DeKosky, and Jeffrey B. Ulmer. The conference will be held in Keystone, Colorado from February 10-14, 2019. Vaccines address pub…
Isaac Jonathan Krauss · BRANDEIS UNIVERSITY · 2019 · $563,012 — Project Summary/Abstract Extensive study of HIV+ individuals in recent years has brought to light many examples of antibodies that can neutralize a broad range of HIV strains and protect against viral challenge in animal models of infection. The portion of viral surface most commonly targeted by suc…
BRUCE Bruce FUTCHER · STATE UNIVERSITY NEW YORK STONY BROOK · 2019 · $305,588 — DESCRIPTION (provided by applicant): Because an amino acid can be encoded by as many as six codons, there are many different ways to encode any particular protein. Biases exist in the way codons are used. A little-studied bias is the "codon pair bias", such that some codons "prefer" to be adjac…
Michael S Diamond · WASHINGTON UNIVERSITY · 2019 · $959,574 — PROJET SUMMARY/ABSTRACT Globally, the four serotypes of DENV cause an estimated 390 million new cases of dengue fever and 500,000 cases of dengue hemorrhagic fever (DHF) per year. Zika virus (ZIKV) is a related emerging virus linked to Guillain-Barre syndrome in adults, and microcephaly, congenital …
David Mitchell Smith · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2019 · $123,468 — Project Summary This application is a proposed renewal of Dr. Davey Smith's K24 grant entitled `Mentoring Translational Research in HIV'. This grant supported the training of over 30 trainees and 80 publications to date. While significant progress in HIV research continues to be made, it is not like…
THOMAS D. SCHMITTGEN · UNIVERSITY OF FLORIDA · 2024 · $76,543 — Abstract microRNA (miRNA) dysregulation influences critical molecular pathways involved in tumor progression in a wide range of cancer types. Therefore, modulating miRNA levels in cancer cells as a novel therapeutic approach has promising potential in cancer treatment. In our parent NCI project, we …